CD274 and familial pancreatic carcinoma: Supporting this approach, recent findings in a pancreatic cancer model demonstrated that co-administration of a PARP inhibitor and anti-PD-L1 therapy synergistically reduced tumor growth and significantly increased T cell infiltration (92).